Company intelligence / Profile preview

HavaHosp

Australia

Ownership: Private
Development stage: Other

Overview

HavaH Therapeutics' lead program T+Ai™, a subcutaneous extended-release pellet combining testosterone and anastrozole, has demonstrated statistically significant reductions in mammographic breast density and background parenchymal enhancement—both indicators of reduced risk for progression to invasive disease—in open-label cohort studies. The company’s ongoing Phase 2 RECAST DCIS study aims to prevent progression of ductal carcinoma in situ to invasive breast cancer. Over 3,500 woman-years of clinical exposure have been accumulated with favorable safety data.[1][2][3]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on HavaHosp.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HavaHosp.

Explore the full profile